The ADDITION-Europe study Simon Griffin, Knut Borch-Johnsen, Melanie Davies, Kamlesh Khunti, Guy Rutten, Annelli Sandbæk, Stephen Sharp, Rebecca Simmons,

Slides:

Advertisements

Similar presentations

Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.

Advertisements

Use of routine care data in research Marit Eika Jørgensen, Chief Physician Bendix Carstensen, Senior Statistician.

The Risk Concept in health care Definition of a risk factor  a disease precursor associated with a higher than average morbidity or mortality rate. John.

Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.

Effectiveness of health checks to improve the physical health of patients with severe mental illness: a single blind cluster randomised controlled trial.

Valsartan Antihypertensive Long-Term Use Evaluation Results

The INSIGHT study - Reliable blood pressure control and additional benefits for hypertensive patients Anthony M Heagerty Department of Medicine Manchester.

Clinical Trial Results. org Based on the Iron (Fe) and Atherosclerosis Study (FeAST) Leo R. Zacharski, MD; Bruce K. Chow, MS; Paula S. Howes, MS, APRN;

Epidemiological evidence for a protective role for statins in Community Acquired Pneumonia British Thoracic Society Winter Meeting 2012, London Yana Vinogradova.

“Influence of age on the management of heart failure: Findings from Get With the Guidelines–Heart Failure (GWTG-HF)” Daniel E. Forman, MD; Christopher.

Is low-dose Aspirin use associated with a reduced risk of colorectal cancer ? a QResearch primary care database analysis Prof Richard Logan, Dr Yana Vinogradova,

Nahal Mavaddat GP and Primary Care Research Unit School for Primary Care Research Self-Rated Health: Determinants and Outcomes.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

Severe Hypoglycemia and Mortality After Cardiovascular Events for Type 1 Diabetic Patients in Sweden Featured Article: Tom W.C. Lung, Dennis Petrie, William.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

SUPPORTING PRIMARY CARE TO ACHIEVE TARGETS. What targets? 1.9 care processes 2.3 health targets (HbA1c, blood pressure, cholesterol) AND IMPORTANTLY Quality.

Joint Effects of Routine Blood Pressure Lowering and Intensive Glucose Control ADVANCE Adapted from EASD 2008.

Journal Club Hallie Lee PharmD Candidate 2013 Mercer University COPHS PHA 618 Geriatrics-Continuous Care Multivitamins in the Prevention of Cardiovascular.

Multiple risk factors raise ischaemic stroke risk comparable to AF in the elderly: A large Chinese insurance analysis from 425,600 Chinese individuals.

1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.

Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.

Impact of HSV-2 suppressive therapy with daily acyclovir on HIV-1 disease progression: a randomized placebo- controlled trial in Rakai, Uganda Steven J.

Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Double-Blind Raloxifene Use for the Heart (RUTH) Trial C. Duvernoy 1, A. Yeo.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.

UNIVERSITY OF CAMBRIDGE Behavioural Science Group Primary Care Unit Behavioural Science Group Primary Care Unit Development and evaluation of very brief.

A Comparison of Sevelamer and Calcium-Based Phosphate Binders on Mortality, Hospitalization, and Morbidity in Hemodialysis: A Secondary Analysis of the.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.

Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,

Slide 1 Downloaded from Population Impact of Losartan Use on Stroke in the European Union (EU)

P Sever (Co-chair), B Dahlöf (Co-chair), N Poulter (Secretary), H Wedel (Statistician), G Beevers, M Caulfield, R Collins, SE Kjeldsen, A Kristinsson,

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.

Selenium supplementation for the primary prevention of cardiovascular disease: a Cochrane review Clinical

Diabetes and the Kidney Richard Kingston Department of Renal Medicine Kent and Canterbury Hospital.

Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from participants in 26 randomised trials Lancet 2010;

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

Cardiovascular risk reduction following diagnosis of diabetes by screening: 1-year results from the ADDITION- Cambridge trial cohort by Morten Charles,

Rebecca K Simmons, Justin B Echouff o-Tcheugui, Stephen J Sharp, Lincoln A Sargeant, Kate M Williams, A Toby Prevost, Ann Louise Kinmonth, Nicholas J Wareham,

The ALERT Trial.

The SPRINT Research Group

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

The Importance of Adequately Powered Studies

Disclosure Consultations and Honoraria Grant Support

Changing demographics and the impact on dementia

RAAS Blockade: Focus on ACEI

on behalf of the LEADER Trial Steering Committee and Investigators

Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Diabetes Journal Club March 17, 2011

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Volume 378, Issue 9786, Pages (July 2011)

Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Baseline predictors for risk of cardiovascular events or all-cause mortality among immigrants with language barriers (N = 87,707). *Adjustment for all.

Increase of physical activity over time associated with lower HF risk

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

16-year follow-up of the DANish Acute Myocardial Infarction 2 (DANAMI-2) trial PG Thranea, SD Kristensena, KKW Olesena, LS Mortensenb, HE Bøtkera, L.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

The ADDITION-Europe study Simon Griffin, Knut Borch-Johnsen, Melanie Davies, Kamlesh Khunti, Guy Rutten, Annelli Sandbæk, Stephen Sharp, Rebecca Simmons, Maureen van den Donk, Nicholas Wareham, Torsten Lauritzen Netherlands Denmark UK

Background Type 2 diabetes is common, costly and associated with a significant burden of morbidity and mortality Single risk factor interventions can reduce risk of complications Intensive multifactorial treatment can halve the risk of CVD in people with longstanding diabetes The effectiveness of multifactorial treatment in people with screen detected diabetes is unknown

Diabetes detectable biochemically Diabetes detectable clinically 0 years~8 years Diabetes detected by screening ~4 years If we find and treat people earlier, can we reduce the chance of them dying early and/or suffering from heart attacks and strokes? Background

The ADDITION-Europe study involves individuals at an earlier stage, i.e. screen detected diabetes is set in daily clinical practice in primary care assesses effectiveness of multifactorial treatment is randomised at the general practice level is pragmatic in design

Five-year data collection 161 practices provided intensive treatment Participants: 1, practices provided routine care Participants: 1,379 Follow-up 1,678 (100%) with endpoint data 104 (6.2%) died Of those alive 1,352 (86%) measured at CRF 1,532 (97%) laboratory data collected Follow-up 1,377 (99.9%) with endpoint data 92 (6.7%) died Of those alive 1,048 (81%) measured at CRF 1,241 (96%) laboratory data collected

Prescribed treatment at baseline Routine care Intensive treatment StatinsBP-loweringGlucose-lowering Baseline

Prescribed treatment at baseline and follow-up Routine care Intensive treatment Baseline Follow up Baseline Follow up Baseline StatinsBP-loweringGlucose-lowering

Prescribed treatment at baseline and follow-up Routine care Intensive treatment Baseline Follow up Baseline Follow up Baseline Follow up Baseline Follow up Baseline StatinsBP-loweringGlucose-lowering

Prescribed treatment at baseline and follow-up Routine care Intensive treatment Baseline Follow up Baseline Follow up Baseline Follow up Baseline Follow up Baseline Follow up Baseline Follow up StatinsBP-loweringGlucose-lowering

Relative risk of composite CVD endpoint as a first event Favours intensive treatment Favours routine care Overall (I-squared = 0.0%) Netherlands Denmark UK Country 0.83 (0.65 to 1.05) 0.96 (0.45 to 2.03) 0.83 (0.59 to 1.16) 0.80 (0.55 to 1.17) Hazard Ratio (95% CI)

Cumulative probability of composite CVD endpoint Primary composite endpoint (%) Years of follow-up RC IT Number at risk p=0.12 Routine care Intensive treatment

Multifactorial intensive treatment was not associated with increased risk of mortality Mortality in both groups was low Results in context All-cause mortality (%) Years of follow-up ADDITION Routine care Danish general registry: Carstensen et al. Diabetologia 2008;51: Danish population with diabetes Danish general population

Conclusions Cardiovascular risk factors improved in both groups in the five years following detection by screening The intervention to promote intensive management was associated with statistically significant but modest differences in prescribed treatment and levels of cardiovascular risk factors These differences were associated with a non-statistically significant 17% relative reduction in the incidence of a composite cardiovascular event endpoint over five years

ADDITION-Europe study team

ADDITION study teams ADDITION-Denmark study group includes Bendix Carstensen, Else-Marie Dalsgaard, Ynna Nielsen, Søren Bech-Morsing, Mette Vinther Skriver, Helle Terkildsen, Morten Charles, Merete Frandsen, Toke Bek and Henrik Andersen ADDITION-Cambridge study group includes Amanda Adler, Judith Argles, Gisela Baker, Rebecca Bale, Roslyn Barling, Daniel Barnes, Mark Betts, Sue Boase, Ryan Butler, Parinya Chamnan, Sean Dinneen, Pesheya Doubleday, Mark Evans, Tom Fanshawe, Francis Finucane, Philippa Gash, Julie Grant, Wendy Hardeman, Robert Henderson, Garry King, Ann-Louise Kinmonth, Joanna Mitchell, Richard Parker, Nicola Popplewell, A. Toby Prevost, Lincoln Sargeant, Megan Smith, Stephen Sutton, Fiona Whittle and Kate Williams. ADDITION-Netherlands study group includes Kees Gorter, Paul Janssen, Lidian Izeboud, Jacqueline Berends, Marlies Blijleven, Bart Thoolen, Denise de Ridder, Jozien Bensing, Mehmet Akarsubasi, Paula Koekkoek, Carla Ruis, Geert Jan Biessels, Jaap Kappelle and Michiel van der Linden. ADDITION-Leicester study group includes Balasubramanian Thiagarajan Srinivasan, David Webb, Laura J Gray, Mary Quinn, Emma Wilmot, Samiul A Mostafa, Nitin Gholap, Hamid Mani, Winston Crasto, Steve Hiles, Joe Henson, Nick Taub, Janet Jarvis, Sukhjit Sehmi, Fiona Ablett, Champa Merry, Emma Healey, Julia Stockman, Sandra Campbell, Janette Barnett, Nil Radia, Mo Radia, Jo Howe, Lesley Bryan, Jane Brela, Jayne Hill, Helen Bray, Rachel Plummer, Zubeir Essat and Francis Pullen